Generic Axert Availability
AXERT (almotriptan malate - tablet;oral)
Manufacturer: JANSSEN PHARMS
Approval date: May 7, 2001
Strength(s): EQ 6.25MG BASE, EQ 12.5MG BASE [RLD]
Has a generic version of Axert been approved?
No. There is currently no therapeutically equivalent version of Axert available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Axert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Issued: October 15, 1996
Inventor(s): Forner; Dolors F. & Duran; Carles P. & Soto; Jose P. & Noverola; Armando V. & Mauri; Jacinto M.
Assignee(s): Laboratorios Almirall S.A.
A compound of formula (I) ##STR1## wherein R.sup.1 and R.sup.2 each represents a hydrogen atom or an alkyl group, Z represents a ring selected from: ##STR2## in which n represents 4, 5 or 6; ##STR3## in which R.sup.3 represents hydrogen or an alkyl group and R.sup.4 represents an alkyl, methoxy benzyl or R.sup.5 NHCO group, R.sup.5 being an alkyl group; and ##STR4## in which R.sup.6 represents an alkyl group. and pharmaceutically acceptable salts thereof are useful in the treatment of migraine and other conditions. They are prepares by decarboxylation of the corresponding indolyl 2-carboxylic acid.Patent expiration dates:
- May 7, 2015✓✓✓
- November 7, 2015✓
- May 7, 2015
- Axert Consumer Information (Wolters Kluwer)
- Axert Consumer Information (Cerner Multum)
- Axert Advanced Consumer Information (Micromedex)
- Axert AHFS DI Monographs (ASHP)
- Almotriptan Consumer Information (Wolters Kluwer)
- Almotriptan Consumer Information (Cerner Multum)
- Almotriptan Advanced Consumer Information (Micromedex)
- Almotriptan Malate AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|